Recent Updates
Recently added Catalysts

GSK580299

Phase 3

Infections, Papillomavirus | Monoclonal antibody | Other |GSK plc|Last Updated: Nov 13, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDDMC
Total Trials4
Total Enrollment2,787
FDA Designations
No designations recorded
Clinical Trials (4)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01190189Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 StudyPHASE3 COMPLETED 137Apr 1, 2011Nov 23, 2017Jun 19, 201928 United States, Canada
NCT01277042Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)PHASE3 COMPLETED 1,212Feb 17, 2011Feb 28, 2012Aug 17, 20181 China
NCT01249365The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 StudyPHASE3 COMPLETED 199Jan 24, 2011Jan 10, 2017Nov 13, 201915 Australia, Portugal +2
NCT00849381Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or ThailandPHASE3 COMPLETED 1,239Apr 1, 2009Dec 1, 2012Sep 12, 20149 Brazil, Taiwan +1
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Subjects Reporting Any, Grade 3 and Related Serious Adverse Events (SAEs)
During the entire study period (from Day 0 up to Month 12)

Assessed SAEs included medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or were congenital anomalies/birth defects in the offspring of a study subject. Any SAE = occurrence of the SAE regardless of intensity grade. Grade 3 SAE = an SAE which prevented normal, everyday activities. Related SAE = an SAE assessed by the investigator as causally related to the study vaccination.

Number of Subjects Reporting Any, Grade 3 and Related Medically Significant Conditions (MSCs)
During the entire study period (from Day 0 up to Month 12)

Medically significant conditions were defined as: AEs prompting emergency room or physician visits that were not (1) related to common diseases, or (2) not related to routine visits for physical examination or vaccination, or as SAEs that were not related to common diseases. Common diseases included: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities and injury. Any MSC = occurrence of the MSC regardless of intensity grade. Grade 3 MSC = a MSC which prevented normal, everyday activities. Related MSC = MSC assessed by the investigator as related to the study vaccination.

Number of Subjects Reporting Any, Grade 3 and Related Potentially Immune-Mediated Diseases (pIMDs)
During the entire study period (from Day 0 up to Month 12)

pIMD(s) are a subset of medically significant conditions (MSCs) that included autoimmune diseases and other inflammatory and/or neurological disorders of interest which may or may not have had an autoimmune aetiology. Any pIMD = occurrence of the pIMD regardless of intensity grade. Grade 3 pIMD = a pIMD which prevented normal, everyday activities. Related pIMD = pIMD assessed by the investigator as related to the study vaccination.

Number of Subjects Reporting Pregnancies and Outcomes of the Reported Pregnancies
During the entire study period (from Day 0 up to Month 12)

Pregnancy is the term used to describe the period in which a fetus develops inside a woman's womb or uterus. In this study, the number of subjects with pregnancies was calculated. The subjects with confirmed pregnancies were followed up to determine the outcomes of the reported pregnancies.

Number of Seroconverted Subjects Against Human Papillomavirus-16 (HPV-16) and HPV-18
One month after third vaccination (Month 7)

A seroconverted subject was defined as a subject seronegative at baseline whose concentration for anti-HPV-16/18 antibodies, as measured by Enzyme-linked Immunosorbent assay (ELISA) , was higher than or equal to (≥) cut-off value. A seronegative subject was defined as a subject whose antibody concentration was below (\<) cut-off value. Cut-off values were 8 ELISA units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.

Number of Subjects Reporting Serious Adverse Events
Throughout the study (from Month 0 to Month 12)

Serious adverse events (SAEs) assessed include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or were a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as the occurrence of any SAE regardless of intensity grade or relation to vaccination. Grade 3 SAE = SAE which prevented normal, everyday activities (in adults/adolescents, such an SAE, for example, prevented attendance at work/school and necessitated the administration of corrective therapy). Related SAE = SAE assessed by the investigator as causally related to the study vaccination.

Number of Subjects Reporting Medically Significant Conditions (MSCs) and Potential Immune-mediated Diseases (pIMDs)
Throughout the study (from Month 0 to Month 12)

Medically significant conditions (MSCs) are defined as: AEs prompting emergency room or physician visits that were not related to common diseases, or not related to routine visits for physical examination or vaccination; SAEs that were not related to common diseases. Common diseases include: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities and injury. Potential immune-mediated diseases (pIMDs) are a subset of medically significant conditions that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Any was defined as the occurrence of any MSC or pIMD regardless of intensity grade or relation to vaccination. Grade 3 MSC or pIMD = a MSC or pIMD which prevented normal, everyday activities. Related MSC or pIMD = a MSC or pIMD assessed by the investigator as related to the vaccination.

Number of Subjects Reporting Pregnancies and Outcome of Reported Pregnancies
Throughout the study (from Month 0 to Month 12)

Live infant NO apparent congenital anomaly; Live infant congenital anomaly; Premature live infant NO apparent congenital anomaly; Premature live infant congenital anomaly; Elective termination NO apparent congenital anomaly; Elective termination congenital anomaly; Therapeutic abortion; Ectopic pregnancy; Spontaneous abortion NO apparent congenital anomaly; Spontaneous abortion congenital anomaly; Stillbirth NO apparent congenital anomaly; Stillbirth congenital anomaly; Molar pregnancy; Pregnancy ongoing; Lost to follow up.

Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)
During the entire study period (up to Month 12)

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Note: Results from one center where compliance issues were discovered are presented also separately.

Number of Subjects With Any, Grade 3 and Related Medically Significant Conditions (MSCs)
During the entire study period (up to Month 12)

MSCs include adverse events prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.

Number of Subjects With Pregnancies and Pregnancy Outcomes
During the entire study period (up to Month 12)

The pregnancy outcomes reported included elective termination, live birth and spontaneous abortion, all of which occurred with no apparent congenital (congenit.) anomalies (anom.) Note: Results from one non-compliant center (NCC) are also presented separately.

Secondary Endpoints
Number of Subjects Seropositive Against HPV-16 and HPV-18
Before vaccination (Month 0) and one month after third vaccination (Month 7)
Concentrations for Anti-HPV-16 and Anti-HPV-18 Antibodies
Before vaccination (Month 0) and one month after third vaccination (Month 7)
Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms
During the 7 days (Days 0 - 6) after any vaccination
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposePREVENTION
Treatment Arms
ArmTypeDescription
Cervarix GroupEXPERIMENTALHealthy female subjects who received control vaccine in the primary study HPV-015 (NCT00294047), were administered three doses of Cervarix vaccine intramuscularly, according to a 0,1,6-month schedule.
Engerix GroupACTIVE_COMPARATORSubjects received a 3-dose vaccination course of the Engerix™-B vaccine administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
HPV vaccineEXPERIMENTALHealthy female subjects aged 26 years and above, who received control vaccine in the primary study NCT00294047, were administrated 3 intramuscular injections of Cervarix vaccine into the deltoid of the non-dominant arm, according to a 0, 1, 6-month schedule in the current study.
Cervarix Compliance Issue Centre GroupEXPERIMENTALSubjects from one centre where compliance issues were discovered, who received the Hepatitis A control vaccine in the primary study (NCT00122681) and the Cervarix vaccine in the current study
Cervarix All Centres GroupEXPERIMENTALSubjects from all study centres who received the Hepatitis A control vaccine in the primary study (NCT00122681) and the Cervarix vaccine in the current study.
Interventions
NameTypeDescription
GSK580299 (Cervarix)BIOLOGICAL3-dose schedule intramuscularly vaccination
GSK580299 (CervarixTM)BIOLOGICAL3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
Engerix-BTMBIOLOGICAL3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
GSK580299, GSK Biological's HPV vaccineBIOLOGICALAll subjects will receive 3 doses administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
Unlock Study Design Details
Eligibility Criteria
Age Range26 Years — N/A
SexFEMALE
Healthy VolunteersYes
Study Sites28

Inclusion Criteria: * Subjects who the investigator believes can and will comply with the requirements of the protocol * A subject previously enrolled in study NCT00294047, who received the control vaccine, and who cannot receive the GSK580299 vaccine because the subject is above the age for which ...

Countries:United StatesCanadaChinaAustraliaPortugalRussiaSingaporeBrazilTaiwanThailand
Unlock Eligibility Criteria